|
gptkbp:instanceOf
|
gptkb:receptor_tyrosine_kinase
gptkb:small_molecule
gptkb:drug
|
|
gptkbp:administeredBy
|
oral route
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2014
|
|
gptkbp:ATCCode
|
L01XE28
|
|
gptkbp:brand
|
gptkb:Zykadia
|
|
gptkbp:CASNumber
|
1032900-25-6
|
|
gptkbp:contraindication
|
hypersensitivity to ceritinib
|
|
gptkbp:developedBy
|
gptkb:Novartis
|
|
gptkbp:eliminationHalfLife
|
41 hours
|
|
gptkbp:hasMolecularFormula
|
C28H36N5O3Cl
|
|
gptkbp:indication
|
ALK-positive metastatic non-small cell lung cancer
|
|
gptkbp:KEGGID
|
D09916
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits ALK phosphorylation
|
|
gptkbp:metabolism
|
liver (CYP3A4)
|
|
gptkbp:molecularWeight
|
558.07 g/mol
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
97.1%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL2219413
57379345
DB09074
29385216
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
fatigue
increased liver enzymes
|
|
gptkbp:target
|
gptkb:anaplastic_lymphoma_kinase
|
|
gptkbp:UNII
|
8L2S730AJK
|
|
gptkbp:usedFor
|
treatment of non-small cell lung cancer
|
|
gptkbp:bfsParent
|
gptkb:Non-Small_Cell_Lung_Cancer
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ceritinib
|